Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT: NCT04567303 · COMPLETED

NCT IDNCT04567303
StatusCOMPLETED
Start Date2020-10-28
Completion2026-08-25
SponsorHoffmann-La Roche (INDUSTRY)
First posted
Last updated

Brief Summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑